News stories about Idera Pharmaceuticals (NASDAQ:IDRA) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Idera Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 45.9311963717437 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Idera Pharmaceuticals, Inc. :IDRA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 (finance.yahoo.com)
- Idera Pharmaceuticals: This ESMO Winner Is A Buy – Seeking Alpha (seekingalpha.com)
- Idera Pharmaceuticals, Inc. (IDRA) Sees Significant Decline in Short Interest (americanbankingnews.com)
- Idera Pharmaceuticals (IDRA) Jumps: Stock Rises 14.4% – Nasdaq (nasdaq.com)
- Idera Pharmaceuticals Inc. (NASDAQ:IDRA) Presents Positive Results – TheOTCReporter.com (blog) (theotcreporter.com)
Several research analysts have recently issued reports on IDRA shares. Zacks Investment Research upgraded shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. BidaskClub downgraded shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. ValuEngine upgraded shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $4.00 target price on shares of Idera Pharmaceuticals in a research report on Tuesday, September 12th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $4.48.
Shares of Idera Pharmaceuticals (NASDAQ IDRA) traded up 5.69% during mid-day trading on Monday, hitting $2.23. 1,623,904 shares of the stock traded hands. The firm’s market capitalization is $333.68 million. Idera Pharmaceuticals has a one year low of $1.30 and a one year high of $3.33. The company’s 50 day moving average is $1.87 and its 200 day moving average is $1.94.
Idera Pharmaceuticals (NASDAQ:IDRA) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Idera Pharmaceuticals had a negative return on equity of 61.09% and a negative net margin of 300.63%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.20 million. On average, equities analysts expect that Idera Pharmaceuticals will post ($0.49) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://stocknewstimes.com/2017/09/18/idera-pharmaceuticals-idra-receives-daily-media-impact-score-of-0-15.html.
About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Ratings for Idera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.